Bayer/Onyx Nexavar Fails Phase III Melanoma Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Onyx is continuing its melanoma program despite sorafenib’s failure to show a progression-free survival benefit in an advanced melanoma study.